Search results
Results from the WOW.Com Content Network
The study analyzed data from over 88,000 people with dementia and over 880,000 control participants who were dementia-free. ... out how to best use these medications to improve dementia outcomes ...
A recent study found that a class of medications called SGLT-2 inhibitors—which does not include Ozempic or similar drugs like Zepbound—significantly lowered the risk of dementia in people ...
More must be done to see whether existing drugs could help to tackle dementia, scientists have said after finding that a number of common treatments may affect a person’s risk. While some new ...
Nicergoline, sold under the brand name Sermion among others, is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Internationally it has been used for frontotemporal dementia as well as early onset in Lewy body dementia and Parkinson's dementia .
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
Vascular dementia can sometimes be triggered by cerebral amyloid angiopathy, which involves accumulation of amyloid beta plaques in the walls of the cerebral arteries, leading to breakdown and rupture of the vessels. [2] [5] Since amyloid plaques are a characteristic feature of Alzheimer's disease, vascular dementia may occur as a consequence ...
Heart problems can increase dementia risk, but a new study suggests that heparin, a common anticoagulant administered via injection, may help delay Alzheimer’s onset.
When the scientists looked at dementia subtypes, they found that SGLT-2 inhibitors were linked to 52% lower risk of vascular dementia, and 39% lower risk of Alzheimer’s disease.